Myelodysplastic Syndroms

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
06921
A pilot phase II study of an intensified remission induction chemotherapy followed by an autologous or allogeneic bone marrow transplantation for bad prognosis myelodysplastic syndromes (MDS) and acute myelogenous leukemia secondary (sAML) to MDS of more than six months duration in patients with age younger than 60 years
06903
A randomized phase III multicenter trial comparing LD-ARA-C alone versus LD-ARA-C + GM-CSF versus LD-ARA-C + recombinant interleukin-3 for patients with myelodysplastic syndromes and a high risk of developing acute leukemia
06902
A pilot multicenter study of recombinant human interleukin-3 (IL-3) plus LD-ARA-C in patients with myelodysplastic syndromes and a risk of developing acute leukemia
06888
A pilot (phase II) study of intensive remission induction chemotherapy for bad prognosis myelodysplastic syndromes (MDS) and acute myelogenous leukemia secondary (sAML) tp MDS of more than 6 months duration in patients with age younger than 60 years
06885
A randomized phase I - II dose-finding study of human GM-CSF in patients with MDS at relatively low risk of developing acute leukemia
06886
Randomized phase II study with GM-CSF and low-dose ARA-C in patients with "high risk" myelodysplastic syndromes
06851
Phase II trial of recombinant alpha-2 interferon in patients with myelodysplastic syndromes
06961
A randomized phase III study for autologous peripheral blood stem cell transplantation (PSCT) vs a second intensive consolidation course after a common induction and consolidation course in patients with bad prognosis MDS and sAML to MDS of more than 6 months duration.
06975
A phase II Multicenter study of Amifostine in patients with myelodysplastic dyndromes at relatively low risk of developing acute leukemia
06891
A randomized phase I/II multicenter study of recombinant human interleukin-3 (IL-3) in patients with myelodysplastic syndromes at relatively low risk of developing acute leukemia.
06013
Idarubicin and Ara-C in combination with Gemtuzumab-Ozogamycin (IAGO) for untreated patients, with or without an HLA identical sibling, with high risk MDS or AML developing after a preceding period with MDS during 6 months duration : a phase II study.
06023
Randomized phase II trial with infliximab (Remicade (R)) in patients with myelodysplastic syndrome and a relatively low risk of developing acute leukemia.
06011
Intravenous low-dose decitabine versus supportive care in elderly patients with primary Myelodysplastic Syndrome (MDS) (>10% blasts or high-risk cytogenetics), secondary MDS or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for intensive therapy: an EORTC-German MDS Study Group randomized phase III study.
06962
A randomized phase III study to assess intensification of the conditioning regimen for allogenic and autologous stem cell transplantation for myeloid and lymphoid malignancies with a high risk of relapse.

Back to Site-list